Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
63 hedge funds and large institutions have $41.7M invested in Neos Therapeutics, Inc in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 17 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
9% less funds holding
Funds holding: 69 → 63 (-6)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
36% less capital invested
Capital invested by funds: $65M → $41.7M (-$23.3M)
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $115K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$12.6M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$11.2M |
| 3 |
BC
Broadfin Capital
New York
|
+$7.35M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.84M |
| 5 |
DM
Deerfield Management
New York
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$2.79M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$2.34M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$1.88M |
| 4 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$1.77M |
| 5 |
NC
Nexthera Capital
New York
|
-$1.51M |
NEOS Hedge Fund Activity: Q4 2018 in Review
63 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q4 2018, worth a combined $41.7M — down 36% from $65M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of NEOS and 11 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 24 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $12.6M. The largest seller was J. Goldman & Co, cutting an estimated $2.79M.
- 63 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q4 2018, down from 69 in Q3 2018.
- Funds reported $41.7M of Neos Therapeutics, Inc stock for Q4 2018, down 36% quarter-over-quarter.
- 11 funds opened new Neos Therapeutics, Inc positions in Q4 2018 and 17 closed out, a net change of -6 holders.
- The largest Neos Therapeutics, Inc buyer in Q4 2018 was Nantahala Capital Management, an estimated $12.6M added.
- The largest Neos Therapeutics, Inc seller in Q4 2018 was J. Goldman & Co, an estimated $2.79M sold.
Based on aggregated 13F filings for Q4 2018.